Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Conditions
Interventions
KPT-9274
Niacin ER
+1 more
Locations
8
United States
UCLA Health
Los Angeles, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Georgetown University, Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
NYU-Laura & Isaac Perlmutter Cancer Center
New York, New York, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Start Date
June 8, 2016
Primary Completion Date
January 26, 2021
Completion Date
January 26, 2021
Last Updated
November 25, 2024
NCT07489378
NCT07181681
NCT07204340
NCT07403721
NCT07395258
NCT06885281
Lead Sponsor
Karyopharm Therapeutics Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions